Advertisement
Conference Highlights: ASCO 2016

Conference Highlights: ASCO 2016

An App to Improve Lung Cancer Survival Comparisons of standard follow-up to web-mediated follow-up among lung cancer survivors are lacking. To address this research gap, investigators studied patients with stage III or IV lung cancer who had completed initial chemotherapy, radiation therapy, or surgery who were randomly assigned to standard follow-up or web-mediated follow-up. Web-mediated follow-up used a web-based application (app) through which patients self-assessed 12 symptoms weekly. The app used an algorithm to assess specific changes in symptoms and triggered email alerts to patients’ clinicians. At 1 year, patients in the web app group had a survival rate of 75%, compared with a rate of 49% observed in the standard care group. Although relapse rates were about 50% for both groups, 74% of patients in the web app group were able to receive the full recommended treatment for disease recurrence, compared with about 33% of those in the standard follow-up group. The web app also reduced the average number of imaging tests needed by 50% per patient per year and required only about 15 minutes per week of clinicians’ time in order to follow patients. —————————————————————-   Hormone Therapy & Breast Cancer Recurrence Previous studies have shown that survivors of early-stage hormone-receptor positive breast cancer have a high risk of recurrence. Options for reducing recurrence are limited. For a study, nearly 2,000 postmenopausal women who had received 5 years of aromatase inhibitor (AI) therapy or any duration of prior tamoxifen were continued on an AI or placebo. After 5 years, women who received AI therapy had a 34% lower risk of recurrence than those who received placebo. Overall...
[ HIDE/SHOW ]